GRAVITON BIOSCIENCE CORP

Profile

Company Names

GRAVITON BIOSCIENCE CORP

Addresses

125 WEST END AVE, SUITE 301, NEW YORK, NY 10023

125 WEST END AVE., SUITE 301, NEW YORK, NY 10023

430 E. 29TH STREET, 9TH FLOOR, NEW YORK, NY 10016

Phone Numbers

1-332-400-0444
332-400-0444

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2020

State Incorporated:

DELAWARE

Total Amount Raised:

$93,319,490.00

Number of Funding Rounds:

4
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
4
2024-01-31 
$24,999,996.00 
$24,999,996.00 
$0.00 
Equity 
3
2023-11-22 
$24,999,998.00 
$24,999,998.00 
$0.00 
Equity 
2
2022-12-20 
$39,819,496.00 
$50,000,000.00 
$10,180,504.00 
Equity 
1
2021-02-04 
$3,500,000.00 
$30,000,000.00 
$26,500,000.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
PHILIP 
 
BARACH 
DIRECTOR
TCW SPECIAL MORTGAGE CREDITS FUND III (CAYMAN), L.P.   |  TCW SPECIAL MORTGAGE CREDITS FUND III, L.P.   |  UST/TCW SENIOR MORTGAGE SECURITIES FUND, L.P.   |  DOUBLELINE OPPORTUNISTIC CMBS/CRE FUND, L.P.   |  DOUBLELINE CRE FINANCE LLC   |  GRAVITON BIOSCIENCE CORP   |  EQUILIBRE BIOPHARMACEUTICALS CORP.   |  STANDARD BIOCARBON CORP
JAMES 
 
BOYLAN 
DIRECTOR
CAMP4 THERAPEUTICS CORP   |  GRAVITON BIOSCIENCE CORP
BIHUA 
 
CHEN 
DIRECTOR
CORMORANT GLOBAL HEALTHCARE FUND, LP   |  CORMORANT GLOBAL HEALTHCARE OFFSHORE FUND, LTD.   |  APELLIS PHARMACEUTICALS, INC.   |  C4 THERAPEUTICS, INC.   |  CORMORANT PRIVATE HEALTHCARE FUND I, LP   |  TP THERAPEUTICS, INC.   |  TP THERAPEUTICS, INC   |  KEZAR LIFE SCIENCES, INC.   |  ATEA PHARMACEUTICALS, INC.   |  CORMORANT PRIVATE HEALTHCARE OFFSHORE FUND II, LP   |  CORMORANT PRIVATE HEALTHCARE FUND II, LP   |  ATIA VISION, INC.   |  SUPIRA MEDICAL, INC.   |  CORMORANT PRIVATE HEALTHCARE FUND III LP   |  CORMORANT PRIVATE HEALTHCARE OFFSHORE FUND III LP   |  ADONA MEDICAL, INC.   |  BLOSSOMHILL THERAPEUTICS, INC.   |  CORMORANT PRIVATE HEALTHCARE OFFSHORE FUND IV LP   |  CORMORANT PRIVATE HEALTHCARE FUND IV LP   |  TIOGA CARDIOVASCULAR, INC.   |  BIVACOR INC.   |  CHROMA MEDICINE, INC.   |  BIOVENTRIX INC   |  TIGER BIOTHERAPEUTICS INC.   |  CORMORANT PRIVATE HEALTHCARE FUND V LP   |  CORMORANT PRIVATE HEALTHCARE OFFSHORE FUND V LP   |  GRAVITON BIOSCIENCE CORP   |  INTERIUS BIOTHERAPEUTICS, INC.   |  CORMORANT PRIVATE HEALTHCARE FUND VI, LP   |  CORMORANT PRIVATE HEALTHCARE OFFSHORE FUND VI, LP   |  AKURA MEDICAL, INC.
RICHARD 
 
GIROUX 
DIRECTOR
GRAVITON BIOSCIENCE CORP
STEVEN 
 
GORDON 
EXECUTIVE OFFICER, DIRECTOR
LILY POND CURRENCY PLUS FUND, LTD.   |  LILY POND CURRENCY FUND LTD   |  LILY POND INVESTORS LTD   |  REFINERY 29 INC.   |  EQUILIBRE BIOPHARMACEUTICALS CORP.   |  GRAVITON BIOSCIENCE CORP
JEREMY 
 
LEVIN 
DIRECTOR
DIGITAL GLOBAL SYSTEMS, INC.   |  ENDOSHUNT MEDICAL, INC.   |  GRAVITON BIOSCIENCE CORP
DAVID 
 
MACMILLAN 
DIRECTOR
DEVERON CORP.   |  GRAVITON BIOSCIENCE CORP
RAN 
 
NUSSBAUM 
DIRECTOR
KITE PHARMA, INC.   |  KEROS THERAPEUTICS, INC.   |  UROGEN PHARMA LTD.   |  LB PHARMACEUTICALS INC   |  GRAVITON BIOSCIENCE CORP
STELIOS 
 
PAPADOPOULOS 
DIRECTOR
EXELIXIS INC   |  BG MEDICINE, INC.   |  SEMBA BIOSCIENCES INC   |  MACINTOSH LLC   |  REGULUS THERAPEUTICS INC.   |  EPIKAST INC.   |  GRAVITON BIOSCIENCE CORP
SAMUEL 
 
WAKSAL 
DIRECTOR
GRAVITON BIOSCIENCE CORP   |  EQUILIBRE BIOPHARMACEUTICALS CORP.
SAMUEL 
D 
WAKSAL 
EXECUTIVE OFFICER, DIRECTOR, PROMOTER
KADMON I LLC   |  KADMON HOLDINGS, LLC   |  GRAVITON BIOSCIENCE CORP
SAMUEL 
D. 
WAKSAL 
EXECUTIVE OFFICER, DIRECTOR
GRAVITON BIOSCIENCE CORP
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2024-02-14
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2024-01-31 
2023-12-04
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2023-11-22 
2023-12-04
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2022-12-20 
2021-02-19
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2021-02-04 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#